Helping MindMed Succeed
MindMed's Founders Have Returned
(Not affiliated with Mind Medicine (MindMed) Inc.)
MindMed's Founders Have Returned
(Not affiliated with Mind Medicine (MindMed) Inc.)
We represent MindMed's original founders who have been working on MindMed since 2009. We have investments in 4.9% of Mind Medicine (MindMed) Inc.'s outstanding shares. We have come back to provide MindMed with a path to success that is less dilutive and more profitable than management's current vision.
We are engaged in actions to suspend MindMed's shelf registration (or at-the-money offering). We believe that shareholder dilution is unwarranted, and we propose that MindMed consider the use of convertible perpetual preferred stock.
Our proposed plan calls for the cutting of MindMed's cash spending to be reduced from $60 million per year to $34 million per year. The plan effectuates this by cutting bloated and redundant positions, eliminating expenses on non-core drugs, and divesting the digital medicine segment.
Our plan significantly cuts MM-120's development time from 7 years to 4 years. Additionally, our plan seeks to realign MM-110 (18-MC) to treat opioid addiction rather than just alleviate the symptoms of withdrawal.
Jake Freeman is the Chief Executive Manager of FCM and Jake has worked in the financial industry since he was 13 years old. Jake has extensive background in quantitative modeling and financial engineering and has authored several papers in that space. Recently, Jake started Freeman Capital Management LLC. Jake's current research interests
Jake Freeman is the Chief Executive Manager of FCM and Jake has worked in the financial industry since he was 13 years old. Jake has extensive background in quantitative modeling and financial engineering and has authored several papers in that space. Recently, Jake started Freeman Capital Management LLC. Jake's current research interests include the Gaussian Reverse Isoperimetry Problem for the Plane, Optimal Capital Structure under non-Gaussian metrics, and Risk Premia in the US Equity Markets. Jake is currently pursuing a Masters in Applied Mathematics at the University of Southern California.
Chad Boulanger is a successful executive with 30+ years of senior level experience providing strategic growth and improving performance and profitability through hands-on management style. With his brother William Boulanger, Chad has overseen the success of Obiter Research. Chad joined Savant to help produce the 18-MC compound. Chad is h
Chad Boulanger is a successful executive with 30+ years of senior level experience providing strategic growth and improving performance and profitability through hands-on management style. With his brother William Boulanger, Chad has overseen the success of Obiter Research. Chad joined Savant to help produce the 18-MC compound. Chad is highly skilled in overseeing start up and reorganizing companies in both an entrepreneurial and a corporate environment and is an effective leader, adept at utilizing out-of-the-box approaches in training and motivating employees to foster team unity toward fulfillment of target goals. Chad received his B.S. from St. Norbert College in Business.
Scott Freeman, M.D. has extensive experience in clinical trial work and FDA regulatory strategy. At MindMed, as Chief Medical Officer, Dr. Freeman established a highly productive collaboration with Professor Liechti which has resulted in significant progress in the research of LSD. As the CMO of Savant he was the primary investigator be
Scott Freeman, M.D. has extensive experience in clinical trial work and FDA regulatory strategy. At MindMed, as Chief Medical Officer, Dr. Freeman established a highly productive collaboration with Professor Liechti which has resulted in significant progress in the research of LSD. As the CMO of Savant he was the primary investigator behind the National Institutes of Health (NIH) grant in bringing 18-MC (now called MM-110) to IND and its first-in-human clinical trial. He served as Vice President of Clinical Development at Onyx Pharmaceutical and was head of both the clinical development and operations groups, which led to FDA approval of Nexavar for kidney and liver cancer. Dr. Freeman has done over two dozen clinical trials (Phase I, Phase II, and Phase III) in a variety of different therapeutic areas in the pharmaceutical industry. He has developed a number of clinical development strategies and has work with the FDA to achieve drug approval. Dr. Freeman was an Associate Professor at Tulane University and a guest researcher at the NIH in both basic and clinical research. Scott earned his BA from the University of Colorado and received his MD from the University of Nevada.